{
    "symbol": "IMV",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 14:17:04",
    "content": " We are accelerating mabropepment towards registration trials by completing Phase IIb clinical proof-of-concept studies that will validate, a, that the DPX delivery platform uniquely makes vaccines in oncology viable; and b, that Mavropepmanes has a derisked path to registration in DLBCL and ovarian cancer. In the first half of next year, we expect to complete enrollment of the first stage of the study and then 6 months following, we will also complete enrollment of the first stage of our Phase IIb of Varian cancer trial, EVAL. In a moment, Jeremy will give more details about the capability of our technology platform compared to other cancer vaccines and how the first results of our clinical trials should validate the broad applicability of DPX and create excitement about our delivery platform amongst the industry. Let's go to the next slide, please. Let's go to the next slide, please."
}